RPCEC00000228尚未招募3 期
A randomized, double blind, phase III clinical trial, to evaluate the ability of the CV638 attenuated live vaccine candidate Vibrio cholerae 638 O1 El Tor Ogawa strain, to prevent clinical cholera disease caused by the challenge with the virulent strain Vibrio cholerae 3008 . - PVSVCHO
Finlay Institute of Vaccines (IFV)0 个研究点目标入组 120 人开始时间: 2016年12月29日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 120
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized controlled trial. Masking: Double Blind. Control group: Placebo. Assignment: Parallel. Purpose: Prevention
入排标准
- 年龄范围
- 18 years 至 45 years（—）
- 性别
- All
入选标准
- •1. Woman or man from 18 to 45 years of age.
- •2. Voluntariness expressed through written informed consent signed by the volunteer.
- •3. Good physical and mental state established by medical criteria by means of anamnesis and physical examination, as well as by electrocardiogram and the following complementary ones: complete blood count with erythrocyte sedimentation, hemoglobin: glycemia, creatinine, urea, uric acid, TGO, TGP, GGT, Alkaline phosphatase, and urine (cituria), within the reference parameters which were not clinically significant, before starting the study.
- •4. Women of childbearing age who meet the following criteria:
- •A.Negative pregnancy rapid test in the previous checkup, before vaccination and before the challenge,
- •B. Agree to practice sexual abstinence or use an approved effective method of birth control within 2 months after vaccination,
- •C. Agree to continue these precautions during the study and up to 30 days after the challenge.
- •5. Man of childbearing age who agrees not to conceive a child within 30 days of vaccination.
- •6. Subject that agrees not to participate in another clinical trial during the period.
排除标准
- •1. Volunteers with VC titers greater than or equal to 320, five days before administration of CV638 or Placebo.
- •2. Volunteers seropositive to cholera antitoxin IgG by ELISA 10 days before CV638 or Placebo administration.
- •3. Acute disease detected in the week prior to the administration of CV638, Placebo.
- •4. Axillary temperature = 37.5 ° C immediately prior to administration of CV638 or Placebo.
- •5. Personal history of chronic illness, except compensated asthma and hypertension.
- •6. History of immunosuppressive therapy (systemic steroids, cytostatics, etc.) or immunostimulants (interferons, transfer factor, gammaglobulins, levamisole, etc.) in the previous 30 days, excluding topical steroids or by inhalation.
- •7. History of therapy with immunoglobulins or blood products during the 6 months prior to administration of CV638 or Placebo.
- •8. History of antibiotic therapy, current or during the 10 days prior to administration of CV638, or Placebo.
- •9. History of cholera in the last 3 years.
- •10. History of immunization with cholera vaccines prior to the first intervention.
- •11. History of allergic reactions to any of the components of research or antacids, as well as to milk or lactose intolerance.
- •12. History of allergic reactions to doxycycline, azithromycin and ciprofoxacin.
- •13. History of Guillain-Barre syndrome.
- •14. Gestation.
- •15. Breastfeeding.
- •16. Clinically abnormal electrocardiogram at the previous check-up, defined as pathological Q waves or significant changes in the ST-T waves; Criteria of left ventricular hypertrophy; And any non-sinus rhythm, excluding isolated contractions.
- •17. Significant clinical abnormality detected on physical examination, including but not limited to pathological murmur, lymphadenopathy, hepatosplenomegaly, or abdominal scar of doubtful origin.
研究者
相似试验
进行中（未招募）
1 期
eoadjuvant chemotherapy with Atezolizumab or Placebo followed by adjuvant Atezolizumab or PlaceboPatients with early breast cancerMedDRA version: 20.0Level: LLTClassification code 10007050Term: CancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2017-002771-25-DESABP Foundation Inc.1,550
进行中（未招募）
1 期
A Randomized, Double-Blind, Phase III Clinical Trial of Neoadjuvant Chemotherapy with Atezolizumab or Placebo in Patients with Triple-Negative Breast Cancer Followed by Adjuvant Continuation of Atezolizumab or Placebo GeparDouzePatients with early breast cancerMedDRA version: 20.0Level: LLTClassification code: 10007050Term: Cancer Class: 10029104CTIS2023-508472-11-00SABP Foundation Inc.1,550
进行中（未招募）
1 期
eoadjuvant chemotherapy with Atezolizumab or Placebo followed by adjuvant Atezolizumab or PlaceboPatients with early breast cancerMedDRA version: 20.0 Level: LLT Classification code 10007050 Term: Cancer System Organ Class: 100000004864EUCTR2017-002771-25-ESSABP Foundation Inc.1,520
进行中（未招募）
1 期
Saline hypertonic in preschoolers and lung structure as measured by computed tomography.Cystic FibrosisEUCTR2015-004143-39-FRErasmus MC120
进行中（未招募）
1 期
Saline hypertonic in preschoolers and lung structure as measured by computed tomography.Cystic FibrosisEUCTR2015-004143-39-NLErasmus MC120